From: Role of resistin as a marker of inflammation in systemic lupus erythematosus
Demographic variables | Value |
---|---|
Patient age, years | 47 (20 to 82) |
Weight, kg | 66 (42 to 99) |
Height, cm | 166 (145 to 182) |
Body mass index, kg/m2 | 24.2 (17.2 to 37.2) |
Menopausal status | |
Premenopausal, n (%) | 72 (44) |
Disease variables | |
Disease duration, years | 11 (1 to 41) |
SLEDAI-2K | 5 (0 to 31) |
SLICC/ACR Damage Index | 2 (0 to 11) |
Kidney affection ever by SLE, n (%) | 40 (25) |
S-creatinine, μmol/L | 87 (49 to 291) |
Glomerular filtration rate, mL/minute | 74 (22 to 172) |
Proteinuria, >3.5 g/24 hours, n (%) | 9 (6) |
End-stage kidney disease, n (%) | 1 (0.6) |
Hemoglobin, g/L | 131 (75 to 158) |
Erythrocyte sedimentation rate, mm/hour | 25 (2 to 125) |
C-reactive protein, mg/L | 5 (3 to 100) |
Cholesterol, mmol/L | 5.4 (2.4 to 9.3) |
High-density lipoprotein, mmol/L | 1.6 (0.5 to 2.8) |
Low-density lipoprotein, mmol/L | 3.1 (<0.1 to 6.3) |
Triglycerides, mmol/L | 1.2 (0.3 to 6.0) |
Albumin, g/L | 40 (11 to 53) |
IgG, g/L | 13.5 (5 to 28) |
IgA, g/L | 2.5 (0.07 to 11) |
IgM, g/L | 1.0 (0.05 to 4.6) |
C3, g/L | 0.93 (0.28 to 1.68) |
C4, g/L | 0.14 (0.02 to 0.28) |
Tumor necrosis factor-alpha, pg/mL | 2.16 (0.40 to 36.96) |
Interleukin-1β, pg/mL | 0.47 (0.0 to 9.65) |
Interleukin-6, pg/mL | 9.67 (2.81 to 119.0) |
sIL-6R, ng/mL | 48.87 (11.56 to 107.15) |
Glucocortocosteroid user, n (%) | 85 (52) |
Glucocorticosteroid dose, mg | 5 (2.5 to 35) |
BMD lumbal spine, g/cm2, mean (SD) | 1.12 (0.18) |
BMD total hip, g/cm2, mean (SD) | 0.92 (0.15) |
BMD femur neck, g/cm2, mean (SD) | 0.89 (0.15) |
BMD radius total, g/cm2, mean (SD) | 0.50 (0.08) |
Number of vertebral fractures per patient | 0 (0 to 11) |
ICTP, μg/L | 3.59 (0.9 to 16.38) |
PINP, μg/L | 43.0 (9.1 to 177.94) |